SUBSCRIBE
SUBSCRIBE

Genentech, Inc.

NEWS
Job Trends
SF Bay Area Jobs; Genentech, Inc. Increased Workforce 24%
May 5, 2006
 · 
1 min read
Biotech Bay
Ready For A Rally
May 2, 2006
 · 
7 min read
Biotech Bay
Genentech, Inc. Is Weird
April 13, 2006
 · 
1 min read
Biotech Beach
The Day In Review: Biotech IPOs Get Chilly Reception
April 12, 2006
 · 
1 min read
Biotech Bay
Genentech, Inc. Just Got Cheaper
April 12, 2006
 · 
1 min read
Biotech Beach
The Day In Review: Genentech, Inc. Outperforms In Q1
April 11, 2006
 · 
1 min read
Biotech Beach
The Day In Review: Pfizer Inc. Buys Another Biotech
April 7, 2006
 · 
1 min read
BioCapital
Pharmaceuticals: Blindsided
April 3, 2006
 · 
1 min read
Biotech Beach
The Day In Review: ViroPharma Incorporated Climbs On Maribavir Results
March 30, 2006
 · 
1 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026
April 30, 2026
 · 
15 min read
Press Releases
Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026
April 30, 2026
 · 
11 min read
Press Releases
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc
April 23, 2026
 · 
20 min read
Press Releases
Genentech’s Fenebrutinib Significantly Reduced Relapses Versus Standard of Care to Approximately One Every 17 Years in RMS
April 22, 2026
 · 
15 min read
Press Releases
Genentech’s Enspryng (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD
April 22, 2026
 · 
12 min read
Press Releases
Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
April 21, 2026
 · 
9 min read
Press Releases
CORRECTING and REPLACING FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus
April 21, 2026
 · 
15 min read
Press Releases
FDA Accepts Application for Genentech’s Gazyva for the Treatment of the Most Common Form of Lupus
April 21, 2026
 · 
14 min read
Press Releases
Roche expands mass spectrometry menu to include steroid assays receiving CLIA ‘moderate complexity’ designation
March 18, 2026
 · 
4 min read
Press Releases
Genentech Provides Update on Phase III persevERA Study in ER-positive Advanced Breast Cancer
March 9, 2026
 · 
7 min read
Load More